Related references
Note: Only part of the references are listed.Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial
Joseph Pidala et al.
BLOOD (2020)
Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors
Juan Montoro et al.
BONE MARROW TRANSPLANTATION (2020)
Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation
Monzr M. Al Malki et al.
BLOOD ADVANCES (2020)
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
Javier Bolanos-Meade et al.
LANCET HAEMATOLOGY (2019)
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma
Sairah Ahmed et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission
Armin Rashidi et al.
BLOOD ADVANCES (2019)
Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy
Scott R. Solomon et al.
BLOOD ADVANCES (2019)
Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD
Nelli Bejanyan et al.
BLOOD ADVANCES (2018)
Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide
Asad Bashey et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide
L. Castagna et al.
BONE MARROW TRANSPLANTATION (2016)
Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation
Nelli Bejanyan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil
Ivan S. Moiseev et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated
Ramzi Abboud et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation
M. Mielcarek et al.
BLOOD (2016)
Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation
M. Mohty et al.
BONE MARROW TRANSPLANTATION (2016)
Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation
Nelli Bejanyan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells
Nicoletta Cieri et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
Madan H. Jagasia et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study
Mohamed L. Sorror et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
Shannon R. McCurdy et al.
BLOOD (2015)
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia
Stefan O. Ciurea et al.
BLOOD (2015)
Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation
Shernan G. Holtan et al.
BLOOD (2015)
Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update
A. Bacigalupo et al.
BONE MARROW TRANSPLANTATION (2015)
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors
J. Peccatori et al.
LEUKEMIA (2015)
Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Brief-Course Sirolimus Following Reduced-Intensity Peripheral Blood Stem Cell Transplantation
Scott R. Solomon et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide
Luca Castagna et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT
Corey Cutler et al.
BLOOD (2014)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Quality of life associated with sirolimus for prevention of graft-versus-host disease: results from a randomized trial
Heather S. L. Jim et al.
HAEMATOLOGICA (2014)
T-Cell-Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation
Asad Bashey et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation
Stefan O. Ciurea et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation
Joseph Pidala et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors
Claudio Anasetti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Fludarabine and Pharmacokinetic-Targeted Busulfan before Allografting for Adults with Acute Lymphoid Leukemia
Stella Santarone et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts
Claudio G. Brunstein et al.
BLOOD (2011)
A NEW MEASURE OF SYMPTOM BURDEN IN CHRONIC GRAFT-VERSUS-HOST DISEASE
L. A. Williams et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Patient-Reported Outcomes for Acute Graft-versus-Host Disease Prevention and Treatment Trials
Stephanie J. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
Leo Luznik et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+T regulatory cells
Heather Kopf et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2007)
Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation
Corey Cutler et al.
BLOOD (2007)
Quality of life associated with acute and chronic graft-versus-host disease
S. J. Lee et al.
BONE MARROW TRANSPLANTATION (2006)
Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells
JJA Coenen et al.
BLOOD (2006)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
ML Sorror et al.
BLOOD (2005)
Perspectives on cancer therapy-induced mucosal injury - Pathogenesis, measurement, epidemiology, and consequences for patients
ST Sonis et al.
CANCER (2004)
Share Paper
